Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV

To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery. Ongoing, nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and infants....

Full description

Saved in:

Bibliographic Details
Published in:	AIDS (London) Vol. 32; no. 6; p. 729
Main Authors:	Mulligan, Nikki, Best, Brookie M, Wang, Jiajia, Capparelli, Edmund V, Stek, Alice, Barr, Emily, Buschur, Shelley L, Acosta, Edward P, Smith, Elizabeth, Chakhtoura, Nahida, Burchett, Sandra, Mirochnick, Mark
Format:	Journal Article
Language:	English
Published:	England 27.03.2018
Subjects:	Adult Chromatography, Liquid Female Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - pharmacokinetics HIV - isolation & purification HIV Infections - drug therapy HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - pharmacokinetics Humans Infant, Newborn Male Oxazines Piperazines Plasma - chemistry Postpartum Period Pregnancy Pregnancy Complications, Infectious - drug therapy Prospective Studies Pyridones Tandem Mass Spectrometry Viral Load Young Adult
ISSN:	1473-5571, 1473-5571
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery. Ongoing, nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and infants. Intensive steady-state 24 h pharmacokinetic profiles after dolutegravir 50 mg once-daily were performed during the second trimester (2T), third trimester (3T) and postpartum. Maternal delivery and postnatal infant samples were collected after birth. Dolutegravir was measured by validated LC-MS/MS; quantitation limit was 0.005 μg/ml. A two-tailed Wilcoxon signed-rank test (α = 0.10) was employed for paired within-subject comparisons. Twenty-nine enrolled participants had a median age of 32 years (range 21-42). Pharmacokinetic data were available for 15 (2T), 28 (3T) and 23 (postpartum) women. Median dolutegravir AUC0-24,Cmax and C24 were 25-51% lower in the 2T and 3T compared with postpartum. The median cord blood/maternal plasma concentration ratio was 1.25 (n = 18). In 21 infants, median elimination half-life was 32.8 h after in utero exposure. Viral load at delivery was less than 50 copies/ml for 27/29 women (93%). Twenty-nine infants were HIV-negative. Renal abnormalities noted on ultrasound in two infants were deemed possibly related to dolutegravir. Dolutegravir exposure is lower in pregnancy compared with postpartum in the same women on once-daily dosing. Median AUC0-24 during pregnancy was similar to, whereas trough concentrations were lower than, those seen in nonpregnant adults. Trough concentrations in pregnancy were well above dolutegravir EC90 (0.064 μg/ml). Dolutegravir readily crosses the placenta. Infant elimination is prolonged, with half-life over twice that of historical adult controls.
AbstractList	To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery. Ongoing, nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and infants. Intensive steady-state 24 h pharmacokinetic profiles after dolutegravir 50 mg once-daily were performed during the second trimester (2T), third trimester (3T) and postpartum. Maternal delivery and postnatal infant samples were collected after birth. Dolutegravir was measured by validated LC-MS/MS; quantitation limit was 0.005 μg/ml. A two-tailed Wilcoxon signed-rank test (α = 0.10) was employed for paired within-subject comparisons. Twenty-nine enrolled participants had a median age of 32 years (range 21-42). Pharmacokinetic data were available for 15 (2T), 28 (3T) and 23 (postpartum) women. Median dolutegravir AUC0-24,Cmax and C24 were 25-51% lower in the 2T and 3T compared with postpartum. The median cord blood/maternal plasma concentration ratio was 1.25 (n = 18). In 21 infants, median elimination half-life was 32.8 h after in utero exposure. Viral load at delivery was less than 50 copies/ml for 27/29 women (93%). Twenty-nine infants were HIV-negative. Renal abnormalities noted on ultrasound in two infants were deemed possibly related to dolutegravir. Dolutegravir exposure is lower in pregnancy compared with postpartum in the same women on once-daily dosing. Median AUC0-24 during pregnancy was similar to, whereas trough concentrations were lower than, those seen in nonpregnant adults. Trough concentrations in pregnancy were well above dolutegravir EC90 (0.064 μg/ml). Dolutegravir readily crosses the placenta. Infant elimination is prolonged, with half-life over twice that of historical adult controls. To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.OBJECTIVETo evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.Ongoing, nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and infants.DESIGNOngoing, nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and infants.Intensive steady-state 24 h pharmacokinetic profiles after dolutegravir 50 mg once-daily were performed during the second trimester (2T), third trimester (3T) and postpartum. Maternal delivery and postnatal infant samples were collected after birth. Dolutegravir was measured by validated LC-MS/MS; quantitation limit was 0.005 μg/ml. A two-tailed Wilcoxon signed-rank test (α = 0.10) was employed for paired within-subject comparisons.METHODSIntensive steady-state 24 h pharmacokinetic profiles after dolutegravir 50 mg once-daily were performed during the second trimester (2T), third trimester (3T) and postpartum. Maternal delivery and postnatal infant samples were collected after birth. Dolutegravir was measured by validated LC-MS/MS; quantitation limit was 0.005 μg/ml. A two-tailed Wilcoxon signed-rank test (α = 0.10) was employed for paired within-subject comparisons.Twenty-nine enrolled participants had a median age of 32 years (range 21-42). Pharmacokinetic data were available for 15 (2T), 28 (3T) and 23 (postpartum) women. Median dolutegravir AUC0-24,Cmax and C24 were 25-51% lower in the 2T and 3T compared with postpartum. The median cord blood/maternal plasma concentration ratio was 1.25 (n = 18). In 21 infants, median elimination half-life was 32.8 h after in utero exposure. Viral load at delivery was less than 50 copies/ml for 27/29 women (93%). Twenty-nine infants were HIV-negative. Renal abnormalities noted on ultrasound in two infants were deemed possibly related to dolutegravir.RESULTSTwenty-nine enrolled participants had a median age of 32 years (range 21-42). Pharmacokinetic data were available for 15 (2T), 28 (3T) and 23 (postpartum) women. Median dolutegravir AUC0-24,Cmax and C24 were 25-51% lower in the 2T and 3T compared with postpartum. The median cord blood/maternal plasma concentration ratio was 1.25 (n = 18). In 21 infants, median elimination half-life was 32.8 h after in utero exposure. Viral load at delivery was less than 50 copies/ml for 27/29 women (93%). Twenty-nine infants were HIV-negative. Renal abnormalities noted on ultrasound in two infants were deemed possibly related to dolutegravir.Dolutegravir exposure is lower in pregnancy compared with postpartum in the same women on once-daily dosing. Median AUC0-24 during pregnancy was similar to, whereas trough concentrations were lower than, those seen in nonpregnant adults. Trough concentrations in pregnancy were well above dolutegravir EC90 (0.064 μg/ml). Dolutegravir readily crosses the placenta. Infant elimination is prolonged, with half-life over twice that of historical adult controls.CONCLUSIONDolutegravir exposure is lower in pregnancy compared with postpartum in the same women on once-daily dosing. Median AUC0-24 during pregnancy was similar to, whereas trough concentrations were lower than, those seen in nonpregnant adults. Trough concentrations in pregnancy were well above dolutegravir EC90 (0.064 μg/ml). Dolutegravir readily crosses the placenta. Infant elimination is prolonged, with half-life over twice that of historical adult controls.
Author	Mulligan, Nikki Smith, Elizabeth Burchett, Sandra Wang, Jiajia Acosta, Edward P Best, Brookie M Capparelli, Edmund V Buschur, Shelley L Chakhtoura, Nahida Stek, Alice Mirochnick, Mark Barr, Emily
Author_xml	– sequence: 1 givenname: Nikki surname: Mulligan fullname: Mulligan, Nikki organization: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California – sequence: 2 givenname: Brookie M surname: Best fullname: Best, Brookie M organization: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California – sequence: 3 givenname: Jiajia surname: Wang fullname: Wang, Jiajia organization: Harvard T.H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, Massachusetts – sequence: 4 givenname: Edmund V surname: Capparelli fullname: Capparelli, Edmund V organization: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California – sequence: 5 givenname: Alice surname: Stek fullname: Stek, Alice organization: University of Southern California School of Medicine, Los Angeles, California – sequence: 6 givenname: Emily surname: Barr fullname: Barr, Emily organization: University of Colorado, Children's Hospital Colorado, Aurora, Colorado – sequence: 7 givenname: Shelley L surname: Buschur fullname: Buschur, Shelley L organization: Baylor College of Medicine-Texas Children's Hospital – sequence: 8 givenname: Edward P surname: Acosta fullname: Acosta, Edward P organization: University of Alabama at Birmingham, Birmingham, Alabama – sequence: 9 givenname: Elizabeth surname: Smith fullname: Smith, Elizabeth organization: Maternal, Adolescent, and Pediatric Research Branch, National Institute of Allergy and Infectious Diseases – sequence: 10 givenname: Nahida surname: Chakhtoura fullname: Chakhtoura, Nahida organization: Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland – sequence: 11 givenname: Sandra surname: Burchett fullname: Burchett, Sandra organization: Children's Hospital Boston – sequence: 12 givenname: Mark surname: Mirochnick fullname: Mirochnick, Mark organization: Boston University School of Medicine, Boston, Massachusetts, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29369162$$D View this record in MEDLINE/PubMed
BookMark	eNpN0E9LwzAYBvAgE_dHv4FIjl46k6xpkuPY1A2GIqjX8rZNt2ib1CTd8Ns7UGHv5XkOP57DO0YD66xG6JqSKSVK3L3Ml1NyclRwfoZGNBWzhHNBByd9iMYhfBwRJ1JeoCFTs0zRjI3Q09I1fdRbD3vjcbcD30LpPo3V0ZQBG4s7r7cWbMRgK9y5EDvwsW_xwbXa4sbsjd3ig4k7vFq_X6LzGpqgr_5ygt4e7l8Xq2Tz_LhezDdJmXLBE1kzqZXSAEqkAhQQWjBZC6IhI6mqRckynVWEKE6ElEVVZUIAI0UplKI1YRN0-7vbeffV6xDz1oRSNw1Y7fqQ0yOjMlVKHunNH-2LVld5500L_jv__wH7Ae-ZYLE
CitedBy_id	crossref_primary_10_1007_s40262_020_00914_x crossref_primary_10_3389_fmed_2022_940644 crossref_primary_10_3390_ph15121533 crossref_primary_10_1007_s11908_022_00774_5 crossref_primary_10_4155_bio_2018_0085 crossref_primary_10_1002_cpt_1748 crossref_primary_10_1007_s40262_020_00977_w crossref_primary_10_1016_j_clp_2024_08_010 crossref_primary_10_1097_INF_0000000000003364 crossref_primary_10_3389_fped_2021_721059 crossref_primary_10_1002_jcph_2240 crossref_primary_10_1007_s40265_020_01379_9 crossref_primary_10_1016_j_antiviral_2018_09_008 crossref_primary_10_2174_1381612825666190320162507 crossref_primary_10_1016_j_bbadis_2021_166206 crossref_primary_10_1097_QAD_0000000000001931 crossref_primary_10_1016_S2352_3018_18_30098_5 crossref_primary_10_3389_fphar_2023_1294579 crossref_primary_10_1007_s40262_018_0684_z crossref_primary_10_1097_QAI_0000000000003652 crossref_primary_10_1111_hiv_13208 crossref_primary_10_1016_S2352_3018_20_30050_3 crossref_primary_10_1016_j_ebiom_2020_103167 crossref_primary_10_1016_j_ogc_2022_10_013 crossref_primary_10_3390_pathogens14080818 crossref_primary_10_1080_17425255_2020_1754792 crossref_primary_10_1097_QAI_0000000000003281 crossref_primary_10_3389_fped_2021_734122 crossref_primary_10_3390_pathogens11121481 crossref_primary_10_1097_FTD_0000000000001039 crossref_primary_10_1002_jcph_2231 crossref_primary_10_3389_fimmu_2020_00153 crossref_primary_10_2217_fvl_2019_0077 crossref_primary_10_1111_jcmm_70557 crossref_primary_10_3389_ftox_2023_1113032 crossref_primary_10_1371_journal_pone_0276473 crossref_primary_10_1093_jac_dkab365 crossref_primary_10_1097_QAD_0000000000002314 crossref_primary_10_1177_09564624251361183 crossref_primary_10_1007_s40262_020_00898_8 crossref_primary_10_1007_s10928_020_09698_w crossref_primary_10_1002_cpt_3343 crossref_primary_10_1093_jac_dkae197 crossref_primary_10_1097_QAI_0000000000002830 crossref_primary_10_1007_s11904_025_00746_z crossref_primary_10_3390_v15071441 crossref_primary_10_1097_COH_0000000000000884 crossref_primary_10_1002_jcph_1777 crossref_primary_10_1097_FTD_0000000000000735 crossref_primary_10_1007_s40121_024_01085_z crossref_primary_10_3389_fnmol_2024_1459877 crossref_primary_10_1007_s11904_024_00688_y crossref_primary_10_1093_toxsci_kfab112 crossref_primary_10_1186_s13256_019_2148_y crossref_primary_10_1016_j_placenta_2022_03_128 crossref_primary_10_1002_psp4_13242 crossref_primary_10_1007_s12035_021_02508_5 crossref_primary_10_1016_S2352_3018_18_30093_6 crossref_primary_10_1002_jia2_25372 crossref_primary_10_1371_journal_pmed_1002895 crossref_primary_10_1097_FTD_0000000000000929 crossref_primary_10_1093_cid_ciaa006 crossref_primary_10_1097_QAI_0000000000002149 crossref_primary_10_3390_pharmaceutics17070913 crossref_primary_10_1093_jac_dkac081 crossref_primary_10_1093_jac_dkz506 crossref_primary_10_3389_fcell_2023_1175917 crossref_primary_10_3390_pharmaceutics15102455 crossref_primary_10_1016_j_taap_2019_02_002 crossref_primary_10_1016_S2352_3018_23_00198_4 crossref_primary_10_1093_cid_ciae242 crossref_primary_10_1007_s40261_024_01390_y crossref_primary_10_1177_1060028019830788 crossref_primary_10_1002_psp4_13251 crossref_primary_10_1007_s40262_020_00897_9 crossref_primary_10_1080_14622416_2024_2441104 crossref_primary_10_1080_17425255_2024_2353762 crossref_primary_10_1093_cid_ciaa1861 crossref_primary_10_1002_cpt_1221 crossref_primary_10_1111_jog_16349 crossref_primary_10_1111_hiv_12721
ContentType	Journal Article
CorporateAuthor	IMPAACT P1026s Protocol Team
CorporateAuthor_xml	– name: IMPAACT P1026s Protocol Team
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1097/QAD.0000000000001755
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1473-5571
ExternalDocumentID	29369162
Genre	Multicenter Study Comparative Study Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase IV
GrantInformation_xml	– fundername: NIAID NIH HHS grantid: U01 AI068616 – fundername: NIAID NIH HHS grantid: UM1 AI068616 – fundername: NIAID NIH HHS grantid: UM1 AI106716 – fundername: NIAID NIH HHS grantid: P30 AI050410 – fundername: NIAID NIH HHS grantid: UM1 AI068632 – fundername: NIAID NIH HHS grantid: UM1 AI068634
GroupedDBID	--- .XZ .Z2 01R 0R~ 1J1 23M 2WC 354 40H 4Q1 4Q2 4Q3 5GY 5RE 5VS 71W 77Y 7O~ 85S 8L- AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAXQO ABASU ABBUW ABDIG ABIVO ABJNI ABPXF ABVCZ ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACDOF ACEWG ACGFS ACILI ACLDA ACOAL ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADGGA ADHPY AE3 AE6 AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHOMT AHQNM AHQVU AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BAWUL BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIK DIWNM E.X E3Z EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B O9- OAG OAH OBH ODMTH OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OPX OVD OVDNE OVIDH OVLEI OVOZU OWU OWV OWW OWX OWY OWZ OXXIT P2P RIG RLZ S4R S4S SJN TEORI TR2 TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM YFH 7X8 ADKSD ADSXY
ID	FETCH-LOGICAL-c4575-8f28e99eaa9747a9a01b28f70ea6049f7c26e6d00950788bdd677a20bc7991f02
IEDL.DBID	7X8
ISICitedReferencesCount	92
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000427976500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1473-5571
IngestDate	Mon Sep 08 08:51:21 EDT 2025 Mon Jul 21 05:58:19 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4575-8f28e99eaa9747a9a01b28f70ea6049f7c26e6d00950788bdd677a20bc7991f02
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/5854536
PMID	29369162
PQID	1991184998
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1991184998 pubmed_primary_29369162
PublicationCentury	2000
PublicationDate	2018-03-27 20180327
PublicationDateYYYYMMDD	2018-03-27
PublicationDate_xml	– month: 03 year: 2018 text: 2018-03-27 day: 27
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	AIDS (London)
PublicationTitleAlternate	AIDS
PublicationYear	2018
SSID	ssj0005088
Score	2.5411274
Snippet	To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery. Ongoing, nonrandomized,... To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.OBJECTIVETo evaluate...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	729
SubjectTerms	Adult Chromatography, Liquid Female Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - pharmacokinetics HIV - isolation & purification HIV Infections - drug therapy HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - pharmacokinetics Humans Infant, Newborn Male Oxazines Piperazines Plasma - chemistry Postpartum Period Pregnancy Pregnancy Complications, Infectious - drug therapy Prospective Studies Pyridones Tandem Mass Spectrometry Viral Load Young Adult
Title	Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV
URI	https://www.ncbi.nlm.nih.gov/pubmed/29369162 https://www.proquest.com/docview/1991184998
Volume	32
WOSCitedRecordID	wos000427976500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT4NAEN6oNcaL70d9ZU28brossAsn01ibeiipiZreyAKLISpgafv7nQGankxM5MCFQGDysfvN6xtC7mxHRtLWETI3wxzf5kwbpZkbAwA0V4lrpfWwCRUE3nTqT9qAW9WWVa7WxHqhTooYY-Q9LNEBbwS8g_vym-HUKMyutiM0NknHBiqDJV1qulYLR_JRdxcpm7muslatc77qPfcHjXRhe8Au6v5OMuvNZrj_39c8IHstzaT9BheHZMPkR2Rn3CbSj0kwQMihUMQym9Gy1a_-gGso20yznJYz845FMlTnCS2Lal4CyBZftJZsoJ8ZBiIoRnHp6OnthLwOH18eRqwdrcBiBwga81LhGd83WqM_oX3NrUh4qeJGS_AZUhULaWSCBAw4hBcliVRKCx7FCj4w5eKUbOVFbs4J9Y3t8cR4wCO1IxQ8NeXKx37YKJGRcLvkdmWpEKCL-Qidm2JRhWtbdclZY-6wbDQ2QoGDBi0pLv5w9yXZBRpTdwoKdUU6Kfy45ppsx8t5Vs1uakzAOZiMfwC-ib9U
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dolutegravir+pharmacokinetics+in+pregnant+and+postpartum+women+living+with+HIV&rft.jtitle=AIDS+%28London%29&rft.au=Mulligan%2C+Nikki&rft.au=Best%2C+Brookie+M&rft.au=Wang%2C+Jiajia&rft.au=Capparelli%2C+Edmund+V&rft.date=2018-03-27&rft.eissn=1473-5571&rft.volume=32&rft.issue=6&rft.spage=729&rft_id=info:doi/10.1097%2FQAD.0000000000001755&rft_id=info%3Apmid%2F29369162&rft_id=info%3Apmid%2F29369162&rft.externalDocID=29369162
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-5571&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-5571&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-5571&client=summon